New project to boost health industry in Chongchuan
A signing ceremony for a project related to the research, development and production of Kansetin®'s second-generation product took place in the Shibei High-Tech Zone in Nantong's Chongchuan district on Jan 8.
The project, funded by Kangma-Healthcode, aims to boost research and development of Kansetin®'s second-generation broad-spectrum antiviral medications and associated medical devices.
Kansetin®'s second-generation product is a cutting-edge broad-spectrum antiviral protein molecule under development by Kangma-Healthcode. The innovative molecule boasts wide-ranging efficacy in combating viruses and preventing infections.
In recent years, the Shibei High-Tech Zone has been advancing the development of the life and health industry, with synthetic biology emerging as a pivotal area of focus. Kangma-Healthcode stands at the forefront globally in non-cellular synthetic protein technology. The company's investment in the zone is expected to enhance the region's reputation and contribute to its development as a global hub for innovative infection-fighting products.
A signing ceremony for a project intended to step up research and development of Kansetin®'s second-generation product is held in the Shibei High-Tech Zone in Nantong's Chongchuan district on Jan 8. [Photo/Nantong Daily]
